NUS Links:
In this study, led by A/Prof Polly Chen, multi-omics approaches revealed that MDA5 loss in ADAR1-deficient livers does not reduce inflammation and dysfunction. Hepatocyte-macrophage interaction via the PGRN-EGFR axis controls responses to endogenous duplex RNAs, with PGRN driving interferon responses and macrophage recruitment. ADAR1 suppresses PGRN-EGFR signalling, helping tumours evade the immune system.
Click here to read more
Acute myeloid leukaemia (AML) is a fast-growing blood cancer that often becomes resistant to standard treatments. This resistance is linked …
Treatment of relapsed/refractory non-Hodgkin’s lymphoma (R/R-NHL) remains one of the most difficult challenges in haematologic malignancies, with many patients exhausting …
Sorafenib is a first-line therapy used to treat advanced liver cancer, but its effectiveness is often reduced due to resistance …